艾昆纬：2024年美国340B药品定价计划规模演进与增长态势研究报告（中译版）（13页）.pdf

1、White PaperThe Size and Growth of the 340B Program in 2024 RORY MARTIN,PHD,IQVIA Market Access Technology Solutions HARISH KARNE,MS,IQVIA Market Access Technology SolutionsTable of contentsAbstract 1Introduction 1Findings 2Channel trends 3Impact of state contract pharmacy bills 5Disease areas 6Limit

2、ations 7Discussion and future outlook 7Data sources 8References 9Acknowledgements 10About the authors 10 |1This study is part of an ongoing series by IQVIA that examines the size and growth of the 340B Drug Pricing Program(“340B program”).In 2024,340B purchases reached$147.8B at list price,growing 1

3、6.7%year-over-year,driven in part by state bills mandating the use of contract pharmacies.Indexed to 2018,340B purchases at list price in 2024 grew by 174.6%,compared to only 53.3%growth for non-340B purchases.We studied the effect of state bills mandating the extension of 340B pricing to drugs disp

4、ensed using contract pharmacies.As of the end of 2024,eight states had passed such bills.The incremental 340B growth in retail and mail contract pharmacies due to state bills was 45.9%from Q1 2024 to Q4 2024,a 9-month period.This growth will lower manufacturer rebate payments,increasing healthcare c

5、osts for state and local government employers and for commercial employers.Potential policy shifts,including state and federal legislation and possible cuts in Medicaid funding,raise questions about future program growth and healthcare costs.IntroductionThe 340B Drug Pricing program is a federal ini

6、tiative in which manufacturers provide substantial,Medicaid-like discounts on qualifying outpatient drugs to participating hospitals and clinics.The program has grown rapidly in recent years,driven by the expanded use of contract pharmacies third-party pharmacies that are contracted with 340B hospit